Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexaria Bioscience Corp

0.1722
-0.0426-19.83%
Volume:3.21K
Turnover:621.54
Market Cap:878.96K
PE:- -
High:0.2000
Open:0.2000
Low:0.1722
Close:0.2148
Loading ...

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

ACCESS Newswire
·
29 Apr

LEXX: Second Quarter Results

Zacks Small Cap Research
·
24 Apr

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

ACCESS Newswire
·
23 Apr

We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully

Simply Wall St.
·
05 Apr

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire
·
03 Apr

Lexaria's Human GLP-1 Study #5 Begins Dosing

ACCESS Newswire
·
02 Apr

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

ACCESS Newswire
·
18 Mar

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

ACCESS Newswire
·
27 Feb

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

ACCESS Newswire
·
24 Feb

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

ACCESS Newswire
·
11 Feb

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

ACCESS Newswire
·
06 Feb

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

ACCESS Newswire
·
05 Feb

Lexaria Releases Annual Letter from the CEO

ACCESS Newswire
·
30 Jan

LEXX: IRB Approval Clears Way for GLP-1 Study #5

Zacks Small Cap Research
·
28 Jan

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

ACCESSWIRE
·
15 Jan

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

ACCESSWIRE
·
14 Jan

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
14 Jan

Lexaria's Registered GLP-1 Study #4 Begins Dosing

ACCESSWIRE
·
19 Dec 2024

Lexaria Forms New Scientific Advisory Board

ACCESSWIRE
·
18 Dec 2024

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

ACCESSWIRE
·
17 Dec 2024